Month: September 2018

From the beginning of this week, President Donald Trump has intensified the ongoing trade war between the world’s two largest economies by imposing new tariffs on Chinese imports. The latest salvo includes 10% tariffs on about $200 billion worth of Chinese goods, which is likely to increase to 25% in January 2019 if Beijing refuses to offer trade concessions. The freshly levied tariff comes on top of a 25% tariff already imposed on about $50 billion worth of imports from China […]

JetBlue Airways Corporation JBLU announced plans to bump up its Palm Springs service with new nonstop flights to Boston. Additionally, the carrier will extend the duration of its current seasonal service to New York JFK. Flights connecting Palm Springs with Boston will operate twice weekly on Mondays and Thursdays beginning Feb 14, 2019 through Apr 30, 2019 […]

Southwest Airlines Co . LUV has announced several nonstop flights as well as plans to resume some of its seasonal services. Consequently, the carrier has extended its bookable flight schedule through Jun 8, 2019 […]

Eli Lilly and Company LLY announced that the FDA has approved its calcitonin gene-related peptide (CGRP) antibody, Emgality (galcanezumab), for the preventive treatment of migraine in adults. The drug is approved as a once-monthly, self-administered, subcutaneous 120 mg injection. The company confirmed about the injection’s imminent launch […]

Global Payments Inc. GPN recently announced that it will acquire SICOM Systems, Inc., a leading provider of Enterprise Technology Solutions from LLR Partners. SICOM offers enterprise, cloud-based software as a service (SaaS) solutions and other such solutions to quick service and fast casual restaurants along with food service management providers around the globe. […]

Nasdaq, Inc . NDAQ remains well-poised for growth, banking on both organic initiatives as well as strategic acquisitions. This Zacks Rank #2 (Buy) company intensified its focus on Market Technology and Information Services businesses, offering the biggest growth opportunities […]

Lennar Corporation LEN is slated to report results for third-quarter fiscal 2018 (ended Aug 31), before the opening bell on Oct 3. In the last reported quarter, the company delivered a positive earnings surprise of 251.1%. This Miami-based homebuilder surpassed expectations in three of the trailing four quarters, the average beat being 65.7%. […]

Verizon Communications Inc. VZ recently announced it has attained live commercial 4G LTE network speeds of 1.45 gigabits per second (Gbps) in New York in collaboration with Nokia Corporation NOK and Qualcomm Technologies, Inc., a subsidiary of QUALCOMM Incorporated QCOM . Notably, these companies used six channel carrier aggregation, a major LTE Advanced technology to reach the high speed. […]

Facebook FB is clearly looking at new options to boost time spent on its platform. The company’s recent announcement to allow users to add music to photos and videos after Stories is a move in this direction. Currently, Facebook is testing the feature and is allowing only few users to explore the option. […]

GrubHub GRUB recently announced the acquisition of Tapingo — a leading mobile-app for campus food delivery services. Valued at $150 million, this transaction is in line with the company’s strategy to expand its market offering and customer base. Tapingo, San Francisco and Israel-based company, already has partnerships with over 150 universities, colleges and professional campuses across the United States and Israel […]

Pfizer Inc. PFE announced that the FDA has approved Vizimpro (dacomitinib) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations. Vizimpro was reviewed and approved under the FDA’s Priority Review program […]

Ultragenyx Pharmaceutical Inc. RARE announced positive top-line safety and efficacy data from the second dose cohort and positive longer-term data from the first dose cohort of the ongoing OTC phase I/II study of its adeno-associated virus (“AAV”) gene therapy candidate — DTX301.DTX301 is being evaluated forthe treatment of ornithine transcarbamylase (OTC) deficiency. […]